A Telematic Program for Optimization of Metabolic Control in Diabetes Mellitus Type 1 (DM1) Patients
A greater visit frequency between the diabetes mellitus 1 (DM1) patient and the medical team increases the possibilities to improve metabolic control. The support of telematic visits can support the patient and the health system.
Patients and Method: 160 patients (from 5 participating centres) with type 1 diabetes mellitus (DM1) candidates for improved metabolic control selected according to inclusion and exclusion criteria. The telecare system used is comprised of the patient Unit and the doctor Unit. The system allows the patient to send glucose values, insulin doses, carbohydrate contribution and other events via the internet. Both the patient and the professional can use this information via the telecare system platform.
The application of interactive telematic systems between patient-health team will improve the cost effectiveness of care programmes for optimisation of metabolic control directed towards diabetes mellitus (DM1) patients.
General Objective Evaluate the impact of the telecare system on the efficiency of economic and clinical management of human and material resources directed to a program of metabolic control optimisation in diabetes mellitus 1 (DM1) patients as well as the level of metabolic control and the quality of life of the patients.
- To identify and analyse the influence of the telecare system on patient costs in time, money and normal work or school activity which the patient has to stop to carry out the physical visits for following the programme.
- To identify and analyse the influence of the telecare system on medical team costs in time, money and care organisation directed towards the monitoring phase of the metabolic control care programme.
- To identify and analyse the influence of the telecare system on the level of metabolic control: Glycosylated haemoglobin and the presence of acute hypoglycemic and hyperglycaemic complications in diabetes mellitus 1 (DM1) patients that follow the metabolic optimisation programme.
- To identify and analyse the influence of the telecare system on the quality of life of the patient measured in satisfaction scale, impact, social/work concern and concern relating to diabetes.
- To identify and analyse the influence of the telecare system on the adherence to different treatment components.
|Diabetes Mellitus, Type 1 Metabolic Disorder||Other: Control Device: Telecare system|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Multicentric Intervention Study Evaluating the Efficiency of the Implementation in the Spanish Health System of a Telematic System Applied to Metabolic Control Optimization for Type 1 Diabetes Mellitus (DM1) Patients|
- Optimise metabolic control [ Time Frame: Month 12 ]
- Insulin dose and criteria (timetables, habits of diet and activity).
- Autocontrol description and survey about perception of hypoglycaemia
- Knowledge about diabetes: Diabetes knowledge questionnaire (DKQ2) <25/35
- Patient costs [ Time Frame: Month 6 ]Time, expenses and ordinary activity (studies and work) that the patient could not do in order to attend to the face-to-face visits.
- Medical team costs [ Time Frame: Month6 ]Time, expenses and healthcare issues used in the follow-up phase of the metabolic control.
- Quality of life [ Time Frame: Month 12 ]Quality-of-life questionnaire designed for diabetes mellitus (EsDQOL) and standardised instrument for use as a measure of health outcome (EuroQoL).
- Treatment adherence [ Time Frame: Month 12 ]Self-Care Inventory-revised (SCI-R), a self-report measure of perceived adherence to diabetes self-care recommendations, among adults with diabetes.
|Study Start Date:||May 2011|
|Study Completion Date:||November 2012|
|Primary Completion Date:||April 2012 (Final data collection date for primary outcome measure)|
Experimental: Interventional telematic
80 patients will be included in this arm. They will receive 5 telematic visits (Telecare system) and 2 face to face visits.
Device: Telecare system
5 telematic visits and 2 face-to-face visits.
80 patients will be included in this arm. They will receive 7 face-to-face visits (not telematic).
7 face-to-face visits.
Other Name: Control group do not use telematic system.
*Title: Multicentric random, prospective, open and comparative intervention study evaluating the efficiency of the implementation in the Spanish Health System of a telematic system applied to metabolic control optimization for type 1 diabetes mellitus (DM1) patients.
1) Pre-intervention. After the patient is informed and accepts the protocol they make 2 visits for planning individual treatment. 2) Random Assignment in 2 Groups: A) Intervention (telecare system). B) Control. The intervention group patients will be trained in the telecare system machine. Both groups will make the same number of 6 visits over 6 months: Intervention Group (5 telematics and 1 hospital), Control group (6 hospital). Results will be assessed at 3 and 6 months and reassessed at 12 months.
- Patients The objective of the present study is to demonstrate that telematic control of diabetes mellitus is not inferior to the face to face visit control system, while showing an added value an important reduction in costs. Cost information from three studies have been used for the calculation of the sample 2,3,20 in diabetes mellitus 1 (DM1) patients, some followed in a telematic form (210 ± 184€) and other in the form of face to face visits (376 ± 278€). Relating to this, 72 patients per group are needed to obtain a statistical power of 99% and an alpha level of 0.05 (two-sided). 80 patients per group will be needed to be randomised taking into account a 10% loss percentage.
- Hospital Clínico. Barcelona
- Hospital Clínico. Valencia
- Hospital Carlos Haya. Málaga
- Hospital Clínico. Madrid
- Hospital de Cruces. Barakaldo
Each arm will include 80 patients, 160 as a total.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01337141
|Hospital de Cruces|
|Barakaldo, Spain, 48903|
|Hospital Clínic de Barcelona|
|Barcelona, Spain, 08036|
|Hospital Clínico de Madrid|
|Madrid, Spain, 28040|
|Hospital Carlos Haya|
|Malaga, Spain, 29010|
|Hospital Clínico de Valencia|
|Valencia, Spain, 46010|
|Principal Investigator:||Enric Esmatjes, MD and PhD||Hospital Clínic de Barcelona (CIBERDEM)|